The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 577-584

  Aghemo, Alessio ^a   Rumi, Maria Grazia ^a   Monico, Sara ^a   Prati, Gian Maria ^a   D'Ambrosio, Roberta ^a   Donato, Maria Francesca ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TYPING; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; MIDDLE AGED; TREATMENT FAILURE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE;

EID: 68549136610     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46.
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-2451.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
6. Dienstag JL, McHutchison JG. American Gastroenterological Association Medical Position Statement on the management of hepatitis C. Gastroenterology 2006; 130:225-230.
7. Modi AA, Hoofnagle JH. New therapies for hepatitis C. Hepatology 2007; 46:615-617.
8. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
9. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
10. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46:1688-1694.
11. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50.
12. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 June 10-12. Hepatology 2002; 36:S3-S20.
13. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1 -infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
14. Soffredini R, Rumi MG, Parravicini ML, et al. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. Am J Gastroenterol 2004; 99:1738-1743.
15. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
16. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
17. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 Weeks: a pilot study. Hepatology 2004; 40:1260-1265.
18. Bailey RJ, Wong VK, Cooper C, et al. Response to peginterferonalfa-2b + ribavirin combination therapy in genotype 2 and 3 patients with poor baseline prognostic factors: results of the Canadian POWER program. Hepatology 2007; 46 Suppl. 1:347A.
19. Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006; 11:797-802.
20. Rumi MG, Aghemo A, D'Ambrosio R, et al. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Ther 2007; 12:1033-1040.
21. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363:1728-1731.
22. Jacobson IM, Brown RS, Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46:971-981.
23. Bruno S, Cammà C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41:474-481.
24. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55:529-535.
25. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-1444.
26. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-7039.
27. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57:516-524.
28. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44:1675-1684.
29. Gerotto M, Dal Pero F, Bortoletto G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006; 44:83-87.
30. Hu Y, Shahidi A, Park S, et al. Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction. Am J Clin Pathol 2003; 119:95-100.
31. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641.
32. Westin J, Lagging M, Dhillon AP, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV-infection. J Viral Hepat 2007; 14:29-35.
33. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotype 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134:416-423.
34. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
35. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.